- Sex-specific risk factors for recurrent venous thromboembolismValérie Olié
INSERM, CEPH Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease team, F94807, Villejuif, France
Thromb Res 130:16-20. 2012..Men have higher risk of recurrent venous thromboembolism (VTE) than women but this sex difference remains unexplained. In addition, whether men and women share same risk factors for recurrent VTE is unclear...
- Hormone therapy and recurrence of venous thromboembolism among postmenopausal womenValérie Olié
Hormones and Cardiovascular disease team, CEPH Centre for research in Epidemiology and Population Health, U1018, INSERM, F94807, Villejuit, France
Menopause 18:488-93. 2011..However, the impact of transdermal estrogens on VTE recurrence risk has not been investigated. The aim of our study was to assess the impact of HT by route of estrogen administration on the risk of recurrent VTE...
- Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogenMarianne Canonico
Hormones and Cardiovascular disease, CESP Centre for researchin Epidemiology and Population Health, U1018, INSERM, Villejuif, France
Menopause 17:1122-7. 2010..However, the differential effects of progesterone and norpregnanes on hemostasis have not yet been investigated...
- Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal womenValérie Olié
INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, Universite Paris Sud, UMRS 1018, Villejuif, France
Curr Opin Hematol 17:457-63. 2010..Transdermal estrogens may be safer but early results need to be confirmed. This review provides a summary of the most recent findings regarding the VTE risk among oral versus transdermal estrogens users...
- Postmenopausal hormone therapy and venous thromboembolismValérie Olié
INSERM, CESP Centre for research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular disease, F 94807 Villejuif, France
Thromb Res 127:S26-9. 2011..Because venous thromboembolism (VTE) is the main harmful effect of HT among young postmenopausal women, reducing VTE risk appears to be a relevant strategy to improve the benefit/risk profile of HT among postmenopausal women...
- Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort studyMarianne Canonico
INSERM Unit 780, Cardiovascular Epidemiology Section, Cedex, France
Arterioscler Thromb Vasc Biol 30:340-5. 2010..Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established...